@article{df24f4ea248e40368efb5e403721c7f3,
title = "Individualized precision targeting of dorsal attention and default mode networks with rTMS in traumatic brain injury-associated depression",
abstract = "At the group level, antidepressant efficacy of rTMS targets is inversely related to their normative connectivity with subgenual anterior cingulate cortex (sgACC). Individualized connectivity may yield better targets, particularly in patients with neuropsychiatric disorders who may have aberrant connectivity. However, sgACC connectivity shows poor test–retest reliability at the individual level. Individualized resting-state network mapping (RSNM) can reliably map inter-individual variability in brain network organization. Thus, we sought to identify individualized RSNM-based rTMS targets that reliably target the sgACC connectivity profile. We used RSNM to identify network-based rTMS targets in 10 healthy controls and 13 individuals with traumatic brain injury-associated depression (TBI-D). These “RSNM targets” were compared with consensus structural targets and targets based on individualized anti-correlation with a group-mean-derived sgACC region (“sgACC-derived targets”). The TBI-D cohort was also randomized to receive active (n = 9) or sham (n = 4) rTMS to RSNM targets with 20 daily sessions of sequential high-frequency left-sided stimulation and low-frequency right-sided stimulation. We found that the group-mean sgACC connectivity profile was reliably estimated by individualized correlation with default mode network (DMN) and anti-correlation with dorsal attention network (DAN). Individualized RSNM targets were thus identified based on DAN anti-correlation and DMN correlation. These RSNM targets showed greater test–retest reliability than sgACC-derived targets. Counterintuitively, anti-correlation with the group-mean sgACC connectivity profile was also stronger and more reliable for RSNM-derived targets than for sgACC-derived targets. Improvement in depression after RSNM-targeted rTMS was predicted by target anti-correlation with the portions of sgACC. Active treatment also led to increased connectivity within and between the stimulation sites, the sgACC, and the DMN. Overall, these results suggest that RSNM may enable reliable individualized rTMS targeting, although further research is needed to determine whether this personalized approach can improve clinical outcomes.",
author = "Siddiqi, {Shan H.} and Sridhar Kandala and Hacker, {Carl D.} and Trapp, {Nicholas T.} and Leuthardt, {Eric C.} and Alexandre Carter and Brody, {David L.}",
note = "Funding Information: The study protocol was funded by the McDonnell Center for Systems Neuroscience (New Resource Proposal) and the Mallinckrodt Institute of Radiology (funding for scans). SHS received fellowship support from the Sidney R. Baer Foundation. SHS received salary support from the Center for Neuroscience and Regenerative Medicine at the Uniformed Services University for Health Sciences. DLB was an employee of Washington University at the time the study was conducted, and is now an employee of the Uniformed Services University of the Health Science, Department of Defense. Funding Information: SHS serves as a scientific consultant for Magnus Medical and a clinical consultant for Kaizen Brain Center and Acacia Mental Health. SHS has received research support from Neuronetics Inc and Brainsway Ltd. SHS owns shares in Brainsway Ltd (publicly-traded) and Magnus Medical (not publicly traded). SHS has served as an speaker on behalf of Otsuka (unbranded educational material) and Brainsway (unbranded scientific material). None of these entities were involved in the present work. DLB has served as a consultant for Pfizer Inc, Intellectual Ventures, Signum Nutralogix, Kypha Inc, Sage Therapeutics, iPerian Inc, Navigant, Avid Radiopharmaceuticals (Eli Lilly & Co), the St Louis County Public Defender, the United States Attorney{\textquoteright}s Office, the St Louis County Medical Examiner, GLG, Stemedica, Luna Innovations, and QualWorld. DLB holds equity in the company Inner Cosmos. DLB receives royalties from sales of Concussion Care Manual (Oxford University Press) and an honorarium from Mary Ann Liebert Inc for services as Editor-in-Chief of Journal of Neurotrauma. No conflicts of interest with the presented work. DLB is an employee of the Department of Defense; the views expressed here do not reflect those of the Uniformed Services University of the Health Sciences, the US Department of Defense, or the US Government. ECL holds equity in the companies Neurolutions and Inner Cosmos. CDH, ECL, and SHS hold intellectual property related to the use of RSNM to target TMS. The remaining authors report no conflicts of interest. Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = dec,
doi = "10.1038/s41598-022-21905-x",
language = "English",
volume = "13",
journal = "Scientific reports",
issn = "2045-2322",
number = "1",
}